Smoking and Nicotine

Smoking is the largest preventable cause of death in modern medicine, and quitting pays off at any age, most of all before 40. Vapes and nicotine pouches drop the smoke but are not harmless, and the idea that nicotine itself slows aging rests on a single mouse study.

If you smoke, quitting is the single biggest thing you can do for your lifespan: use varenicline, cytisine, combination nicotine replacement or a nicotine e-cigarette, each of which substantially raises your chance of success. If you don't smoke, don't take up vaping or pouches, and don't use nicotine as a supplement.

How much smoking costs

The population evidence on smoking is about as strong as anything in modifiable-risk epidemiology: huge prospective cohorts with hard endpoints, a clear dose-response and consistent results everywhere. Tobacco kills more than 7 million people a year worldwide, including over 1.6 million non-smokers exposed to second-hand smoke.[1]

In a large contemporary US cohort, current smokers died at about three times the rate of never-smokers and lost more than a decade of life.[2] The half-century study of 34,439 male British doctors found that persistent smokers lost about 10 years, and that between half and two-thirds of them were eventually killed by the habit: about half of those born in 1900–1909, and about two-thirds of those born in the 1920s, who had smoked more intensively from early adult life.[3] In a UK study of a million women, about two-thirds of the deaths of smokers in their 50s, 60s and 70s were caused by smoking.[4] These modern risks are higher than older textbook figures, because the full lifetime hazard only became visible once whole cohorts had smoked from adolescence to old age.[5]

Second-hand smoke is not a minor exposure. Non-smokers exposed to it carry roughly 25–30% higher coronary-heart-disease risk and 20–30% higher lung-cancer risk,[6] and about 20–30% higher stroke risk.[7] Teenagers with measurable second-hand exposure had about 4.7 times the odds of metabolic syndrome in US survey data.[8]

Quitting pays at any age

The earlier you quit, the more you get back. In the US cohort, people who quit at 25–34, 35–44 or 45–54 gained back about 10, 9 and 6 years of life, and quitting before about 40 avoided roughly 90% of the excess risk of death.[9] Women who stopped before about 40 carried only about a tenth of the excess mortality of continuing smokers, and those who stopped before 30 almost none.[10]

It is never too late to gain. A 2024 pooled analysis of about 1.5 million adults in four countries found quitting at any age linked to longer survival: lower death risk showed up within 3 years, even for people who quit in their 40s and 50s, and people off cigarettes for 10 years or more had survival close to never-smokers'.[11] Men in the British doctors study who quit at 60 still gained about 3 years.[12] Both are observational.

Quitting often brings weight gain. In three large US cohorts, people who had quit 2 to 6 years earlier had a somewhat higher diabetes risk than people who kept smoking; the excess peaked 5 to 7 years after quitting, was seen only in people who gained weight, and then faded. Their risk of dying from heart disease or any cause still fell sharply, with or without the weight gain.[13]

How to quit: what the trials show

The cessation evidence is high-certainty. A Cochrane network meta-analysis found that varenicline and cytisine (two drugs that partly mimic nicotine at its receptor) roughly double quit rates against placebo, and that combination nicotine replacement and nicotine e-cigarettes rank among the most effective options.[14] Varenicline raises the chance of quitting about 2.3-fold across dozens of trials, and cytisine works about as well: head-to-head trials found no clear difference, with perhaps a small edge for varenicline.[15] Two large placebo-controlled, manufacturer-funded US trials have since confirmed that cytisine helps: on a 12-week course, about 1 in 5 people stayed off cigarettes continuously from week 9 to week 24, against about 1 in 20 on placebo.[16][17]

A large head-to-head trial randomised 8,144 smokers in 16 countries. At the end of treatment, 33.5% were abstinent on varenicline, 23.4% on the nicotine patch, 22.6% on bupropion and 12.5% on placebo. It found no significant excess of psychiatric side effects from varenicline or bupropion, which led the US regulator to remove its boxed warning on them in 2016. The makers of varenicline and bupropion funded the trial, which is worth keeping in mind.[18]

Nicotine replacement therapy works best as a patch plus a fast-acting form. In short-term quitting trials, serious heart events were rare and not clearly more common than with placebo, but the data are imprecise and the main review was written with a tobacco company; cardiovascular events overall, mostly minor ones, were about twice as common with nicotine replacement.[19][20] E-cigarettes help more people quit than nicotine replacement, on high-certainty evidence.[21]

In pregnancy, smoking raises the risk of fetal growth restriction, low birth weight and perinatal death, and obstetric guidance is to advise stopping every tobacco product, e-cigarettes included, with counselling, behavioural support and medication.[22] In trials with pregnant smokers, nicotine replacement showed no clear harm to babies, though its benefit for quitting is uncertain (low-certainty evidence).[23]

What smoking does to the aging body

Smoking shows up on almost every biological-aging marker, though the size of each effect varies a lot.

  • Epigenetic clocks. Lifetime smoking (pack-years, smoking parents, starting young) speeds up the GrimAge clock in older adults, and that faster clock partly explains smokers' higher mortality.[24] In US adults aged 50–84, each standard-deviation rise in blood cotinine (a nicotine breakdown product) went with about 1.4 years of extra GrimAge2 acceleration.[25] The best-known single smoking mark on DNA, in the AHRR gene, moves back toward never-smoker levels the longer someone has been smoke-free, though some difference can persist for decades.[26] See also environmental toxins.
  • Lung tissue. One small reanalysis, mostly of lung-cancer surgery samples, found smokers' lung tissue about 4 years older on an epigenetic clock; airway, cheek and oesophagus cells showed no significant gap, and ex-smokers' airway cells looked like non-smokers' while their lung tissue did not. A hint, not proof, that some damage persists.[27]
  • Telomeres. Smokers' blood-cell telomeres are slightly shorter on average across 30 pooled studies, with only a weak link to pack-years.[28]
  • Muscle. In a small study of 8 long-term heavy smokers and 8 non-smokers in their 60s, smokers built muscle protein more slowly and had more activity in genes that block muscle growth and break muscle down. Muscle loss itself was not measured, so this is a plausible route, not proof.[29] Nicotine also narrows blood vessels, which may limit oxygen and amino-acid delivery to working muscle, and one line of research links nicotine plus a high-fat diet to fat build-up and mitochondrial abnormalities in muscle.
  • Metabolism. Nicotine damages insulin-producing cells in animals and drives insulin resistance, which makes "vaping for weight loss" a poor trade against other ways to manage weight. In a cross-sectional study of about 800 young Korean adults, current smokers had about 2.4 times the odds of metabolic syndrome, and former smokers did not.[30]
  • Brain. In three large ageing cohorts in England, continental Europe and the US, people who quit had slightly slower memory and verbal-fluency decline over the next six years than those who kept smoking.[31] In a separate US cohort, people who had quit 9 or more years earlier had no higher dementia risk than never-smokers, while recent quitters did.[32] Both are observational. See dementia prevention.

Vapes, pouches and patches are not interchangeable

Most of the harm of smoking comes from combustion, not nicotine. That makes the delivery method the main variable.

ProductHeart and circulationLungsMain concerns
CigarettesAtherosclerosis, clots, heart attack and strokeCOPD, emphysema; linked to about 80% of US lung-cancer deaths[33]More than 7,000 chemicals, including tar, carbon monoxide and cadmium
E-cigarettesAcute small rise in heart rate and blood pressure; no clear excess of heart attack or stroke in exclusive vapers so far (short follow-up); dual use about as risky as smokingReduced lung function; asthma odds about 1.3 timesAldehydes and heavy metals from heated coils
Oral pouchesAcute sympathetic spikes; long-term effects unstudiedNegligibleFast, high-pH nicotine delivery; addictive; trace nitrosamines possible
Nicotine patchMild, transient rise in heart rate and blood pressure; no clear excess of serious events in short trials (imprecise)NoneSteady dosing; used medically to quit

The ranking these data support is cigarettes far worst, then vapes and pouches, then patches. None of it makes vapes or pouches sensible long-term habits for healthy adults: the absence of decades of data is doing a lot of the work for them.

On e-cigarettes, right after a vaping session heart rate rises by about 1.4 beats per minute and blood pressure by about half a mm Hg, and blood markers of blood-vessel-lining activation and platelet stickiness go up.[34] Cohorts followed for about four years have not shown a clear rise in heart attacks or strokes in people who only vape, but follow-up is short and events are few, while people who both vape and smoke carry roughly smoking-level risk.[35][36] The popular claim that vaping is "95% less harmful" comes from a 2014 expert-opinion exercise, not a measurement, and has been sharply criticised.[37][38] The 2019 vaping lung-injury outbreak was caused overwhelmingly by vitamin E acetate in illicit THC cartridges, not regulated nicotine liquid.[39]

Nicotine pouches deserve more scepticism than they get. US bench testing found about 1.3–6.1 mg of nicotine per pouch at a pH of about 6.9–10.1, the alkaline chemistry that maximises absorption,[40] US sales rose several-hundred-fold between 2016 and 2020,[41] and the American Heart Association states that no data exist on their cardiovascular or health risks.[42]

Smokeless tobacco is not one risk category. Low-nitrosamine Swedish snus sits well below cigarettes but is not risk-free: in never-smoking Swedish men, snus users had roughly 28% higher all-cause and about 27% higher cardiovascular mortality than men who never used tobacco, with a borderline rise in cancer deaths (about 12%); the risks rose with years of use, not with the amount used per week.[43] At the other end, smokeless tobacco and areca nut together caused an estimated 120,000 oral cancers in 2022, about 31% of the world total, mostly in low- and middle-income countries.[44]

Nicotine on its own: small effects, real cautions

Thinking. In 41 double-blind lab studies, a single dose of nicotine gave small-to-moderate gains in fine motor skill, alertness, attention speed and short-term memory, in non-smokers and in smokers not deprived of nicotine; working-memory accuracy did not improve.[45] The effect does not seem to last: in a two-year trial in 348 people aged 55–90 with mild cognitive impairment, a daily nicotine patch did not improve memory or overall clinical status (registry results, not yet published).[46]

Sport. In the ten exercise studies available, 12 of 16 performance measures showed no effect of nicotine, two improved and two got worse.[47] In one small study of 10 trained male cyclists, a nicotine patch reduced forearm blood flow and slightly raised core temperature during exercise, which its authors read as a heat-illness risk; no heat illness was measured.[48] It is weak evidence, but the precaution costs nothing.

Teenagers. In rodents, adolescent nicotine exposure permanently shortens nerve-cell branches in the hippocampus and predisposes to adult depression and learning problems, mirroring the relapse and cognitive signals in people who start young.[49] Vaping marketed to teenagers is a public-health failure, not harm reduction.

The low-dose nicotine longevity idea

The idea comes from one mouse study, and it should not be over-read. Male mice given low-dose nicotine in their drinking water from 6 to 12 months of age (young adult to middle age) showed restored activity of NAMPT, an enzyme in the NAD+ recycling pathway, higher NAD+, preserved movement and exploration, and more stable telomere-associated proteins, through a route independent of the usual nicotine receptors. Many measurements used three animals per group, and lifespan was not tested.[50]

There is no human trial of nicotine as an NAD+ booster or anti-aging drug, and nicotine is highly addictive: anyone with a history of nicotine addiction should treat experimental low-dose use with extreme scepticism. The NAD+ approaches with human data are covered under Geroprotectors.

What to actually do

  1. If you smoke, quit, and use a treatment. Varenicline or cytisine, a nicotine patch combined with a fast-acting form, or a nicotine e-cigarette; ask a doctor or a stop-smoking service.
  2. If you switch to vaping, switch completely and plan to stop vaping too.
  3. If you don't smoke, don't start vapes or pouches, and keep them away from teenagers.
  4. If you are pregnant and smoke, ask for quit support, and discuss nicotine replacement with your clinician.
  5. Don't use nicotine for performance, memory or longevity, and skip it before endurance exercise in the heat.

Further reading

  • World Health Organization. Tobacco fact sheet. 2026.[51]
  • Doll R et al. Mortality in relation to smoking: 50 years' observations on male British doctors. BMJ 2004.[52]
  • Jha P et al. 21st-century hazards of smoking and benefits of cessation in the United States. N Engl J Med 2013.[53]
  • Pirie K et al. The 21st century hazards of smoking and benefits of stopping: a prospective study of one million women in the UK. Lancet 2013.[54]
  • Lindson N et al. Pharmacological and electronic cigarette interventions for smoking cessation in adults: component network meta-analyses. Cochrane Database Syst Rev 2023.[55]
  • Anthenelli RM et al. Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES). Lancet 2016.[56]
  • Lindson N et al. Electronic cigarettes for smoking cessation. Cochrane Database Syst Rev 2026.[57]
  • Klopack ET et al. Lifetime exposure to smoking, epigenetic aging, and morbidity and mortality in older adults. Clin Epigenetics 2022.[58]
  • Heishman SJ et al. Meta-analysis of the acute effects of nicotine and smoking on human performance. Psychopharmacology 2010.[59]
  • Bloomberg M et al. Cognitive decline before and after mid-to-late-life smoking cessation: a longitudinal analysis of prospective cohort studies from 12 countries. Lancet Healthy Longev 2025.[60]
  • Yang L et al. Nicotine rebalances NAD+ homeostasis and improves aging-related symptoms in male mice by enhancing NAMPT activity. Nat Commun 2023.[61]
  • Byhamre ML et al. Swedish snus use is associated with mortality: a pooled analysis of eight prospective studies. Int J Epidemiol 2021.[62]

— § —